We would love to hear your thoughts about our site and services, please take our survey here.
If we see an RNS reporting 'big director buying' I personally would be inclined to add.
At £8 it was priced to continue to grow, acquiring businesses with high proportion of share consideration instead of cash. It's clear those days are over, for the moment at least, but now at 1/20th of the SP this is bargain basement stuff. I personally trust MS to come through this and, whether it's by improving the metrics or selling, I expect to make a multiple of my investment here.
So, if I understand correctly, you're suggesting big director buying, enough to move the SP 20%, is a sell signal ??
The dip here is a clear opportunity to add. This is undervalued compared to peers on any metric you care to use. Same can be said for most UK shares at the moment. This won't persist.
DH
For Andy0107
“not fantasy theories of Quebe reducing their short etc”
Err… it was a theory yes but hardly fantasy as it was based on a variety of evidence.
Meanwhile, your assertion that the trade in question was a sell was based solely on the reporting being sandwiched between trades at a much higher level is flawed for various reasons.
I did my best to explain it, as far as my limited but not uninformed understanding goes, but you are free to disregard my opinion.
Notwithstanding my irritation at the glee of the regular doom mongers I must admit I am disappointed with this - as I'm sure most of us are - the performance hurdle is taking the p*** ! and for someone who was preaching about saving lives being his motivation it just looks very greedy.
Let's hope the lack of news was all part of AN's greedy plan to drop the SP and get his options on the cheap and he will now inundate us with good news..... I am unlikely to forgive him though...
NB for the poster who talks about no options for other senior employees - read the RNS, the 'staff' got 9m options.
Looking on LSE trade reporting this trade was "off-book" with trade flag "TNCP" which is a "non price forming trade".
I would be pretty confident that this was Qube closing the last of their short - "off-book" would suggest they found someone willing to sell in volume off the market - a trade of that size would take a while to work through in the normal market and would move the price so maybe somebody took the opportunity to offload a chunk, quietly.
This is of course speculation on my part.
Always nice to see shorts getting burnt though.
A trade of that size is more than likely to be reported late and so the comparison with the Bid at the time reported isn't necessarily conclusive. I can't see the trade any more so I don't know what time it was but it's surely going to be a buy if the Bid ends up going much higher afterwards ? Late reported trades are noted as such in the trade code - if you hover it gives you the full description of the trade type. 2.9m could well be the remainder of Qube's short which had dipped under 0.5% (3.4m approx) last time they reported it. So I'd say it was possible. There are no longer any shorts above 0.5%.
either shorts covering or rumours that we haven't heard yet.
I personally I believe Apollo are attempting daylight robbery with their derisory offers - fair enough, worth a try but I don't believe the majority of shareholders would vote to accept an offer anywhere near these levels. I wouldn't.
Realbites - pokerchips has already explained it but if you look at the Rule 2.9 announcement RNS from yesterday it explains the disclosure rules in detail.
The NEDs buying shares would be encouraging but it depends on whether they are in a closed period i.e. whether they have price sensitive info - they would have to wait until it's in the public domain.
If they took on the role then you would think they were confident in the success of the business and if so then buying shares at these prices ought to be a no brainer ??
I don't think it's common for NEDs to get "performance shares" but someone else might correct me on that.
The potential commerciality is not the issue - it’s the abject failure to deliver the technical progress required to get to the market.
Solid state batteries will be huge. Will Ilika be able to play its part ?? Time will tell but this latest trading update is an admission that they are woefully behind.
That is a car crash update.
I suspect the ‘order of magnitude’ error on ShortEurope is because, being Europeans, they have not taken into account the fact that we Brits price in pennies and measure value in pounds.
Hence their short value for Kintbury Capital is 5 billion pennies i.e. £50m (approx).
Just a theory. Otherwise their numbers are nonsense, as has been suggested.
I looked up ‘Trucheck’ and found the following:
It is a genetic screening test offered by an Indian outfit called Datar Cancer Genetics. Very little info on their website but i think it is similar to Cellsearch technology. I did find the following statement in their FAQ:
“Trucheck™ is not intended to be and should not be considered as a substitute for any recommended screening methods”
It is also only available as a lab test and not available in the US.
They have recently achieved a ‘breakthrough device’ nod from the FDA for a prostate cancer test which means they are aiming for FDA clearance.
The ‘synthesisclinic.co.uk’ you linked to do also offer the Guardant ctDNA liquid biopsy.
Ctdna does not offer the opportunity to harvest live, whole ctcs which Parsortix does - and has FDA approval - only metastatic breast cancer so far but the hard work for the device is done.
There is plenty of room for all these technologies and Parsortix but the key thing for me is that there are things you can do with living ctcs that you can’t with ctdna or dead cells harvested chemically.
Jake, talking of comparisons with McDonald’s is ridiculous.
And talk of ‘franchising’ is irrelevant - I'm sure there are a variety of financial structures possible for a buyer to fund the Parsortix machine and consumables - I don’t particularly care at this stage.
What’s important is to get the technology adopted.
The NHS probably won’t be an early adopter but I wouldn’t rule it out - the benefits are tangible - much cheaper than surgical biopsy and the ability to do regular longitudinal monitoring of response to drugs could dramatically improve outcomes.
Currently too many cancer patients are given expensive drug therapy which doesn’t work. Regular liquid biopsies could find this out sooner enabling the therapy to be changed.
‘Personalised’ cancer treatment is the direction of travel and Parsortix can play a key role in this - surely it’s only a matter of time ??